{"title": "Vacuna conjugada SF2a-TT15 en voluntarios adultos sanos", "author": null, "url": "https://ichgcp.net/es/clinical-trials-registry/NCT02797236", "hostname": "ichgcp.net", "description": "Este es el primer estudio en humanos, de un solo centro, simple ciego, aleatorizado con observador enmascarado, escalado de dosis (dos dosis) y controlado con p.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "2016-04-18", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Vacuna conjugada SF2a-TT15 en voluntarios adultos sanos\n[Institut Pasteur](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Institut%20Pasteur)\nUn estudio de fase I de aumento de dosis para evaluar la seguridad y la inmunogenicidad de la vacuna conjugada SF2a-TT15 contra S. Flexneri 2a en voluntarios adultos sanos\nDescripci\u00f3n general del estudio\nEstado\nCondiciones\nIntervenci\u00f3n / Tratamiento\nDescripci\u00f3n detallada\nLos sujetos ser\u00e1n asignados a una de dos cohortes.\n- La cohorte 1 recibir\u00e1 la dosis m\u00e1s baja de 2 \u03bcg de vacuna (con o sin adyuvante de alumbre) o el placebo correspondiente.\n- La cohorte 2 recibir\u00e1 la dosis m\u00e1s alta de 10 \u03bcg de vacuna (con o sin adyuvante de alumbre) o el placebo correspondiente.\nLos sujetos elegibles ser\u00e1n aleatorizados para recibir la dosis de 2 \u03bcg o 10 \u03bcg sin o con alumbre o el placebo correspondiente, en una proporci\u00f3n de 3:1, como tres inyecciones IM \u00fanicas. Habr\u00e1 un intervalo de 28(\u00b13) d\u00edas) entre cada tratamiento.\nEl estudio se llevar\u00e1 a cabo con un enfoque gradual en el que un grupo \"Pionero\" de 2 sujetos (uno que reciba la vacuna activa y otro que reciba el placebo equivalente) recibir\u00e1 la primera inyecci\u00f3n. Estos sujetos permanecer\u00e1n internados para una observaci\u00f3n m\u00e9dica de 24 horas despu\u00e9s de la primera inyecci\u00f3n (no se requiere en las inyecciones subsiguientes) Una vez que se haya establecido que no hay problemas de seguridad en los Grupos \"Pioneer\" sin adyuvante (y despu\u00e9s de que no menos de 48 horas), se inyectar\u00e1 el siguiente grupo \"Pioneer\" (un sujeto que recibe una vacuna con adyuvante de 2 \u03bcg y otro que recibe el placebo de alumbre correspondiente).\nSi no surgen problemas de seguridad en este grupo, despu\u00e9s de no menos de 48 horas, el resto de los sujetos pueden recibir la primera inyecci\u00f3n.\nTipo de estudio\nInscripci\u00f3n (Actual)\nFase\n- Fase 1\nContactos y Ubicaciones\nUbicaciones de estudio\n-\nIsrael\n-\n-\nTel Aviv, Israel\n- Tel Aviv Souraski Medical Center\n-\n-\nCriterios de participaci\u00f3n\nCriterio de elegibilidad\nEdades elegibles para estudiar\nAcepta Voluntarios Saludables\nG\u00e9neros elegibles para el estudio\nDescripci\u00f3n\nCriterios de inclusi\u00f3n\n- Sujetos en buen estado de salud general seg\u00fan la opini\u00f3n del investigador seg\u00fan lo determinado por la historia cl\u00ednica, los signos vitales y un examen f\u00edsico.\n- Ant\u00edgeno leucocitario humano (HLA) -B27 negativo y sin antecedentes de artritis reactiva\n- Serolog\u00edas negativas para VIH, Hepatitis B y Hepatitis C.\n- Niveles en sangre de anticuerpos Shigella flexneri 2a LPS IgG \u2264 percentil 80\n- Sin antecedentes conocidos de abuso de alcohol\nCriterio de exclusi\u00f3n\n- Sujetos con antecedentes de trastornos gastrointestinales cl\u00ednicamente significativos o con antecedentes de diarrea frecuente, n\u00e1useas o emesis, independientemente de la etiolog\u00eda.\n- Individuos con enfermedades inmunosupresoras o bajo terapia inmunosupresora\n- Historia de la cultura probada S. flexneri.\n- Individuos que tienen contacto dom\u00e9stico con/o exposici\u00f3n \u00edntima a un individuo con S. flexneri confirmado por laboratorio.\n- Haber viajado a pa\u00edses/\u00e1reas altamente end\u00e9micas de S. flexneri en los 3 meses anteriores a la inscripci\u00f3n.\n- Participaci\u00f3n previa en cualquier estudio en el que se haya administrado una vacuna candidata contra Shigella.\n- Contraindicaci\u00f3n conocida, hipersensibilidad y/o alergia al producto en investigaci\u00f3n o a sus excipientes.\n- Hipersensibilidad conocida y/o alergia a cualquier medicamento o vacuna\n- Mujeres embarazadas o en per\u00edodo de lactancia, o en edad f\u00e9rtil que no hayan usado o no planeen usar medidas aceptables de control de la natalidad durante la duraci\u00f3n del estudio.\nPlan de estudios\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nDetalles de dise\u00f1o\n- Prop\u00f3sito principal: Prevenci\u00f3n\n- Asignaci\u00f3n: Aleatorizado\n- Modelo Intervencionista: Asignaci\u00f3n paralela\n- Enmascaramiento: \u00danico\nArmas e Intervenciones\n|\n|\nGrupo de participantes/brazo\n|\n|\nIntervenci\u00f3n / Tratamiento\n|\n|\nExperimental: dosis de vacuna 1\nVacuna SF2a-TT15, 2 \u03bcg\n|\n|\nExperimental: vacuna dosis 1+ adyuvante\nVacuna SF2a-TT15, 2 \u03bcg + alumbre\n|\n|\nExperimental: dosis de vacuna 2\nVacuna SF2a-TT15, 10 \u03bcg\n|\n|\nExperimental: vacuna dosis 2 + adyuvante\nVacuna SF2a-TT15, 10 \u03bcg + alumbre\n|\n|\nComparador de placebos: Placebo\nTamp\u00f3n Tris\n|\n|\nComparador de placebos: Placebo + adyuvante\nTamp\u00f3n Tris + Alumbre\n\u00bfQu\u00e9 mide el estudio?\nMedidas de resultado primarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nAcontecimiento adverso\nPeriodo de tiempo: 12 meses\n|\n|\nSeguridad: Ocurrencia, frecuencia, gravedad y duraci\u00f3n de eventos adversos (EA) locales y sist\u00e9micos, incluidas anomal\u00edas de laboratorio cl\u00ednicamente significativas, despu\u00e9s de la administraci\u00f3n de la vacuna SF2a-TT15.\n|\n|\n12 meses\nMedidas de resultado secundarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nInmunogenicidad - Respuesta inmune humoral\nPeriodo de tiempo: 12 meses\n|\n|\nRespuesta de anticuerpos s\u00e9ricos (IgG IgM, IgA) frente a S. flexneri 2a LPS, tras la administraci\u00f3n de las distintas dosis de vacuna y c\u00e9lulas secretoras de anticuerpos frente a S. flexneri 2a LPS, tras la administraci\u00f3n de las distintas dosis de vacuna\n|\n|\n12 meses\nColaboradores e Investigadores\nPatrocinador\nPublicaciones y enlaces \u00fatiles\nPublicaciones Generales\n-\n[Cohen D, Atsmon J, Artaud C, Meron-Sudai S, Gougeon ML, Bialik A, Goren S, Asato V, Ariel-Cohen O, Reizis A, Dorman A, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard LA, Phalipon A. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study. Lancet Infect Dis. 2021 Apr;21(4):546-558. doi: 10.1016/S1473-3099(20)30488-6. Epub 2020 Nov 10.](https://pubmed.ncbi.nlm.nih.gov/33186516)\nFechas de registro del estudio\nFechas importantes del estudio\nInicio del estudio (Actual)\nFinalizaci\u00f3n primaria (Actual)\nFinalizaci\u00f3n del estudio (Actual)\nFechas de registro del estudio\nEnviado por primera vez\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\nPublicado por primera vez (Estimar)\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (Actual)\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n\u00daltima verificaci\u00f3n\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nPalabras clave\nT\u00e9rminos MeSH relevantes adicionales\n-\n[Enfermedades del Sistema Digestivo](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Digestive%20System%20Diseases)\n-\n[Infecciones](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Infections)\n-\n[Enfermedades Gastrointestinales](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Gastrointestinal%20Diseases)\n-\n[Gastroenteritis](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Gastroenteritis)\n-\n[Enfermedades intestinales](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Intestinal%20Diseases)\n-\n[Infecciones por bacterias gramnegativas](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Gram-Negative%20Bacterial%20Infections)\n-\n[Infecciones bacterianas](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Bacterial%20Infections)\n-\n[Infecciones bacterianas y micosis](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Bacterial%20Infections%20and%20Mycoses)\n-\n[Infecciones por enterobacterias](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Enterobacteriaceae%20Infections)\n-\n[Disenter\u00eda Bacilar](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Dysentery%2C%20Bacillary)\n-\n[Disenter\u00eda](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Dysentery)\n-\n[Efectos fisiol\u00f3gicos de las drogas](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs)\n-\n[Factores inmunol\u00f3gicos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunologic%20Factors)\n-\n[Vacunas](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Vaccines)\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- 2015-060\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre Shigelosis\n-\nNCT05987488A\u00fan no reclutandoVoluntarios Saludables\n-\nNCT05961059A\u00fan no reclutandoShigelosis | Disenter\u00eda Bacilar\n-\nNCT05959616A\u00fan no reclutando\n-\nNCT05156528Reclutamiento\n-\nNCT05121974ReclutamientoShigelosis\n-\n-\nNCT03854929TerminadoDiarrea | Shigelosis | Disenter\u00eda, Shigella\n-\nNCT05182749Activo, no reclutando\n-\nNCT04992520Activo, no reclutando\n-\nEnsayos cl\u00ednicos sobre Placebo\n-\nNCT06041269Reclutamiento\n-\nNCT06041984A\u00fan no reclutandoColonoscopia | Glicopirrolato\n-\nNCT06042270A\u00fan no reclutando\n[Respuestas termorreguladoras de los bomberos en incendios activos con suplementaci\u00f3n con beta\u00edna (FFBET)](https://ichgcp.net/es/clinical-trials-registry/NCT06042270)Inflamaci\u00f3n | Cambios de temperatura corporal | Deshidrataci\u00f3n de agua corporal\n-\nNCT06042257A\u00fan no reclutandoHiperactividad en ni\u00f1os con s\u00edndrome de Down | Impulsividad en ni\u00f1os con s\u00edndrome de Down\n-\nNCT06041152A\u00fan no reclutandoDeterioro cognitivo leve amn\u00e9sico\n-\nNCT06040905A\u00fan no reclutando\n[Efecto causal de la nutrici\u00f3n de la coenzima Q10 y la disfunci\u00f3n cognitiva en la tormenta metab\u00f3lica (hiperglucemia y sarcopenia) y el factor neurotr\u00f3fico derivado del cerebro](https://ichgcp.net/es/clinical-trials-registry/NCT06040905)Hiperglucemia | Enfermedad de Alzheimer | Defecto cognitivo leve | Pre-sarcopenia\n-\nNCT06041217A\u00fan no reclutando\n-\nNCT06042153A\u00fan no reclutandoDiabetes tipo 2 | Enfermedad renal en etapa terminal en di\u00e1lisis\n-\nNCT06041165Reclutamiento\n-\nNCT06041789A\u00fan no reclutando", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT02797236", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT02797236&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT02797236", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Institut%20Pasteur", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Shigellosis", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Bacillary%20Dysentery", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Placebo", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=SF2a-TT15%20vaccine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=SF2a-TT15%20vaccine%20%2B%20adjuvant", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Placebo%20%2B%20adjuvant", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=SF2a-TT15%20vaccine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=SF2a-TT15%20vaccine%20%2B%20adjuvant", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=SF2a-TT15%20vaccine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=SF2a-TT15%20vaccine%20%2B%20adjuvant", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Placebo", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Placebo%20%2B%20adjuvant", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Institut%20Pasteur", "https://pubmed.ncbi.nlm.nih.gov/33186516", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=safety", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Immunogenicity", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Phase%20I", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Healthy%20adults", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=conjugate%20vaccine", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=Shigella%20flexneri%202a", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Digestive%20System%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Gastrointestinal%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Gastroenteritis", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Intestinal%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Gram-Negative%20Bacterial%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Bacterial%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Bacterial%20Infections%20and%20Mycoses", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Enterobacteriaceae%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Dysentery%2C%20Bacillary", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Dysentery", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunologic%20Factors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Vaccines", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT05987488", "https://ichgcp.net/es/clinical-trials-registry/NCT05961059", "https://ichgcp.net/es/clinical-trials-registry/NCT05959616", "https://ichgcp.net/es/clinical-trials-registry/NCT05156528", "https://ichgcp.net/es/clinical-trials-registry/NCT05121974", "https://ichgcp.net/es/clinical-trials-registry/NCT05073003", "https://ichgcp.net/es/clinical-trials-registry/NCT03854929", "https://ichgcp.net/es/clinical-trials-registry/NCT05182749", "https://ichgcp.net/es/clinical-trials-registry/NCT04992520", "https://ichgcp.net/es/clinical-trials-registry/NCT04056117", "https://ichgcp.net/es/clinical-trials-registry/NCT06041269", "https://ichgcp.net/es/clinical-trials-registry/NCT06041984", "https://ichgcp.net/es/clinical-trials-registry/NCT06042270", "https://ichgcp.net/es/clinical-trials-registry/NCT06042257", "https://ichgcp.net/es/clinical-trials-registry/NCT06041152", "https://ichgcp.net/es/clinical-trials-registry/NCT06040905", "https://ichgcp.net/es/clinical-trials-registry/NCT06041217", "https://ichgcp.net/es/clinical-trials-registry/NCT06042153", "https://ichgcp.net/es/clinical-trials-registry/NCT06041165", "https://ichgcp.net/es/clinical-trials-registry/NCT06041789", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/austria", "https://ichgcp.net/es/cro-list/country/cameroon", "https://ichgcp.net/es/cro-list/country/colombia", "https://ichgcp.net/es/cro-list/country/egypt", "https://ichgcp.net/es/cro-list/country/georgia", "https://ichgcp.net/es/cro-list/country/liberia", "https://ichgcp.net/es/cro-list/country/nigeria", "https://ichgcp.net/es/cro-list/country/oman", "https://ichgcp.net/es/cro-list/country/paraguay", "https://ichgcp.net/es/cro-list/country/saint_lucia", "https://ichgcp.net/es/cro-list/country/slovakia", "https://ichgcp.net/es/cro-list/country/south_korea", "https://ichgcp.net/es/cro-list/country/venezuela", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/ghana/company/54gene_s_clinical_programs_group_cpg", "https://ichgcp.net/es/cro-list/country/ghana/company/sgs", "https://ichgcp.net/es/cro-list/country/ghana/company/across_global", "https://ichgcp.net/es/cro-list/country/ghana", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT02797236", "https://ichgcp.net/de/clinical-trials-registry/NCT02797236", "https://ichgcp.net/clinical-trials-registry/NCT02797236", "https://ichgcp.net/es/clinical-trials-registry/NCT02797236", "https://ichgcp.net/fr/clinical-trials-registry/NCT02797236", "https://ichgcp.net/it/clinical-trials-registry/NCT02797236", "https://ichgcp.net/hu/clinical-trials-registry/NCT02797236", "https://ichgcp.net/nl/clinical-trials-registry/NCT02797236", "https://ichgcp.net/no/clinical-trials-registry/NCT02797236", "https://ichgcp.net/pl/clinical-trials-registry/NCT02797236", "https://ichgcp.net/pt/clinical-trials-registry/NCT02797236", "https://ichgcp.net/fi/clinical-trials-registry/NCT02797236", "https://ichgcp.net/sv/clinical-trials-registry/NCT02797236", "https://ichgcp.net/cs/clinical-trials-registry/NCT02797236", "https://ichgcp.net/ru/clinical-trials-registry/NCT02797236", "https://ichgcp.net/ja/clinical-trials-registry/NCT02797236", "https://ichgcp.net/zh/clinical-trials-registry/NCT02797236", "https://ichgcp.net/ko/clinical-trials-registry/NCT02797236", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}